Delamanid

Delamanid is an antibacterial medication used for the treatment of tuberculosis. It is specifically used, along with other tuberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.

Medical uses

Delamanid is used in combination with other antituberculosis medications to treat adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Side effects

Common side effects include nausea, vomiting, and dizziness. Serious side effects may include QT prolongation and a type of irregular heart beat known as torsades de pointes.

Mechanism of action

Delamanid is a nitroimidazole antimycobacterial agent. It inhibits the synthesis of mycolic acids, thereby inhibiting the growth of Mycobacterium tuberculosis.

History

Delamanid was developed by Otsuka Pharmaceutical and approved for medical use in the European Union in April 2014.

Society and culture

As of 2016, delamanid is one of the newer medications used to treat tuberculosis. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.

See also

• List of antibiotics
• List of World Health Organization Essential Medicines

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia